Loading patent…
AssigneeThe Trustees of Columbia University in the City of New York
InventorShi Du Yan
Estimating the term…
We have discovered that LRG-47 (also called p47 GTPase), plays a central role in the pathogenesis of multiple sclerosis, and that inhibition of LRG-47 activity by anti-LRG-47 antibodies or of LRG-47 expression by siRNA dramatically reduce the pathology and symptoms of multiple sclerosis. Certain embodiments of the invention are directed to the therapeutic use of anti-LRG-47 antibodies (mouse or rabbit or other antibodies that are humanized or human antibodies to LRG-47, preferably antibodies made against human LRG-47) or siRNA or antisense nucleotides that specifically hybridize with the gene or mRNA or cDNA encoding human LRG-47 to treat or prevent multiple sclerosis and other autoimmune diseases that are T-cell-mediated. Other embodiments are directed to methods for the diagnosis of multiple sclerosis or to determining the aggressiveness of multiple sclerosis by determining the amount of human LRG-47 or LRG-47 mRNA in a biological sample from the patient.
A method for treating or preventing an autoimmune disease in a patient, comprising administering a therapeutically effective amount of an isolated anti-LRG-47 antibody or biologically active fragment or variant thereof or a compound that reduces LRG-47 expression.
A method for treating or preventing an autoimmune disease in a patient, comprising:
The anti-human LRG-47 antibody 138AB or a biologically active fragment or variant thereof.
A pharmaceutical composition comprising an isolated anti-LRG-47 antibody that is a member selected from the group comprising the anti-human LRG-47 antibody 138AB, humanized LRG-47 (A-19) antibody, humanized LRG-47 (M-95) antibody, humanized LRG-47 (M-16) antibody, and humanized LRG-47 (P-20) antibody or a biologically active fragment or variant thereof.
A method for diagnosing a patient who is at risk of developing an autoimmune disease, comprising
Dependencies are inferred from the claim text.